REG - Beximco Pharma. - Request of Extension to Publish Q1 Results

Beximco PharmaceuticalsAnnouncement

13/11/2025 16:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251113:nRSM4773Ha&default-theme=true

RNS Number : 4773H  Beximco Pharmaceuticals PLC  13 November 2025

13 November 2025

 

BEXIMCO PHARMACEUTICALS PLC.

 

Request of Extension to Publish First Quarter Results for the Three-Month
Period Ended 30 September 2025

 

Beximco Pharmaceuticals PLC. ("the Company"; AIM Symbol: BXP, LEI No.:
213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical
products and active pharmaceutical ingredients, announces that the Company has
written to the Bangladesh Securities and Exchange Commission (BSEC), the Dhaka
Stock Exchange and the Chittagong Stock Exchange to request an extension to
submit and publish its first quarter financial results for the three-month
period ended 30 September 2025.

 

In order to approve the first quarter results for the Company, for the
three-month period ended 30 September 2025, a meeting of the Board of
Directors is required. This is not possible currently because, in line with
the Company's previous announcements, dated 21 March 2025, 21 May 2025 and 15
September 2025, BSEC's proposed appointment of an additional nine independent
non-executive directors to the Company's Board of Directors remains
outstanding in the High Court of Bangladesh. This also follows a similar
requests made by the Company on 27 April 2025 and 27 October 2025, in respect
of seeking an extension to publish its Q3 financial results, for the quarter
ended 31 March 2025, and financial results for the year ended 30 June 2025
respectively.

 

As previously announced on 15 September 2025, the Company believes that the
High Court's decision on the BSEC Order will not be forthcoming until November
2025. Further announcements will be made as appropriate.

 

 

For further information please visit www.beximcopharma.com
(http://www.beximcopharma.com/)  or enquire to:

 

 Beximco Pharma
 Mohammad Ali Nawaz, Chief Financial Officer

 Tel: +880 2 58611001, Ext. 20030

 Mohammad Asad Ullah, FCS

 Executive Director & Company Secretary

 Tel: +880 2 41060531, Ext. 10140

 SPARK Advisory Partners Limited (Nominated Adviser)

 Mark Brady / Andrew Emmott

 Tel: +44 (0)20 3368 3551 / 3555

 SP Angel Corporate Finance LLP (Broker)

 Matthew Johnson

 Tel: +44 (0) 20 3470 0470

 FTI Consulting

 Simon Conway / Sam Purewal

 Tel: +44 (0)20 3727 1000

 

Notes to Editors

 

About Beximco Pharmaceuticals PLC.

Beximco Pharma is a leading manufacturer and exporter of medicines based in
Bangladesh. Since its inception in 1976, the Company remains committed to
health and wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics encompasses
diverse delivery systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers, sterile
ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser
solutions, oral soluble films etc. The Company also undertakes contract
manufacturing for multinational and leading global generic pharmaceutical
companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by
global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more than 50
countries. More than 6000 employees are driving the company towards achieving
its aspiration to be among the most admired companies in the region.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMZMMMDFLGKZM



            Copyright 2019 Regulatory News Service, all rights reserved